Thomas Shea is an Oncology physician affiliated with University of North Carolina at Chapel Hill. OpenAlex indexes 331 publications with 12,090 citations (h-index 50); ClinicalTrials.gov lists 10 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
101 Manning Dr
Chapel Hill, NC 275990001
Telephone
919-966-4996Provider last certified this registry record 10 Aug 2021.
Clinical trials
- Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin Lymphoma
Sponsor: UNC Lineberger Comprehensive Cancer Center
- Bortezomib and Romidepsin in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Sponsor: Virginia Commonwealth University
- Clofarabine and Gemtuzumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Sponsor: UNC Lineberger Comprehensive Cancer Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Daiichi Sankyo Inc.Program year20241 payment
- Daiichi Sankyo Inc.Program year20222 payments
- Daiichi Sankyo Inc.Program year20214 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2019)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
43.4%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor43.4%Valacyclovir100%Part D<11 patientsMetabolism & gastrointestinal
25.7%Corticosteroid25.7%Prednisone100%Part D≥12 patientsNervous system
23%SNRI14.5%Duloxetine Hcl100%Part D<11 patientsGabapentinoids8.6%Gabapentin100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
4 NIH research awards on record, funded 1992–2013 per NIH RePORTER. The latest:
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma
Journal of Clinical Oncology
2020
Similar KOLs
Other experts from the same institution or the same specialty.
Lisa Carey, MD
University of North Carolina at Chapel Hill
Robert Sandler, MD
University of North Carolina at Chapel Hill
Diana Perkins, MD
University of North Carolina at Chapel Hill
Hyman Muss, MD
University of North Carolina at Chapel Hill
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”